Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Senti Biosciences (SNTI) Long-Term Debt Issuances (2021)

Senti Biosciences' quarterly Long-Term Debt Issuances came in at $250000.0 in Q4 2021, little changed quarter-over-quarter from $250000.0 in Q3 2021.

Senti Biosciences has reported Long-Term Debt Issuances for 1 years, with the latest figure at $250000.0 in Q4 2021.

  • For the quarter ending Q4 2021, Long-Term Debt Issuances changed N/A year-over-year to $250000.0; the trailing twelve-month figure through Sep 2023 stood at $250000.0 (down 66.67% YoY), and the FY2022 full-year result was $5.2 million, changed N/A from the prior year.
  • Long-Term Debt Issuances for Q4 2021 stood at $250000.0, roughly flat from $250000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Issuances was $250000.0 in Q2 2021, with the low at $250000.0 in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.73 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Senti Biosciences Holdings 22.25 Mn 22.25 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 250,000.00
Dec 31, 2021 250,000.00
Sep 30, 2021 250,000.00
Sep 30, 2021 250,000.00
Jun 30, 2021 250,000.00
Jun 30, 2021 250,000.00